Venture capital continued its love affair with biotechnology in the second quarter, with investment in biotech reaching record levels.
Venture capitalists invested $1.84 billion in 122 biotech deals in the period, according to a MoneyTree report released Monday by PricewaterhouseCoopers and the National Venture Capital Association, using Thomson Reuters data.